Acinic cell carcinoma of the parotid gland: Timeo Danaos et dona ferentes? A multicenter retrospective analysis focusing on survival outcome.


Journal

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 13 05 2022
accepted: 30 05 2022
pubmed: 10 6 2022
medline: 15 11 2022
entrez: 9 6 2022
Statut: ppublish

Résumé

To analyze the demographic data, surgical and adjuvant treatment data and the survival outcomes in adult patients affected by acinic cell carcinoma of the parotid gland (AciCC). A retrospective multicenter analysis of patients treated for AciCC of the parotid gland from 2000 to 2021 was performed. Exclusion criteria were pediatric (0-18 years) patients, the absence of follow-up and patients with secondary metastatic disease to the parotid gland. Multivariable logistic regression was used to determine factors associated with survival. The study included 81 adult patients with AciCC of the parotid gland. The median age was 46.3 years (SD 15.81, range 19-84 years), with a gender female prevalence (F = 48, M = 33). The mean follow-up was 77.7 months (min 4-max 361, SD 72.46). The 5 years overall survival (OS) was 97.5%. The 5 years disease-free survival (DFS) was 60%. No statistical differences have been found in prognosis for age (< 65 or ≥ 65 years), sex, surgery type (superficial vs profound parotid surgery), radicality (R0 vs R1 + Rclose), neck dissection, early pathologic T and N stages and adjuvant therapy (p > 0.05). This study did not find prognostic factor for poorest outcome. In contrast with the existing literature, our results showed how also high-grade tumours cannot be considered predictive of recurrence or aggressive behaviour.

Identifiants

pubmed: 35678874
doi: 10.1007/s00405-022-07481-w
pii: 10.1007/s00405-022-07481-w
pmc: PMC9649501
doi:

Substances chimiques

Glucosamine N08U5BOQ1K

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5821-5829

Informations de copyright

© 2022. The Author(s).

Références

Kirschnick LB, Silveira FM, Schuch LF, Fonseca FP, Martins MAT, Lopes MA et al (2021) Clinicopathological analysis of oral and maxillofacial acinic cell carcinoma: a systematic review. J Oral Pathol Med 50(8):741–749
doi: 10.1111/jop.13159
Cavaliere M, De Luca P, Scarpa A, Savignano L, Cassandro C, Cassandro E et al (2020) Acinic cell carcinoma of the parotid gland: from pathogenesis to management: a literature review. Eur Arch Otorhinolaryngol 277(10):2673–2679
doi: 10.1007/s00405-020-05998-6
Gupta A, Koochakzadeh S, Neskey DM, Nguyen SA, Lentsch EJ (2020) Incidence and survival trends of parotid malignancies over 42 years. Head Neck 42(9):2308–2315
doi: 10.1002/hed.26172
Nasse D (1892) Die Geschwülste Der Speicheldrüsen Und VerwandteTumoren Des Kopfes. Arch Klin Chir. 44:233–302
Buxton RW, Maxwell JH, French AJ (1953) Surgical treatment of epithelial tumors of the parotid gland. Surg Gynecol Obstet 97:401–416
Godwin JT, Foote FW, Fazell EL (1954) Acinic cell adenocarcinoma of the parotid gland; report of twenty-seven cases. Am J Pathol 30:465–477
Vander Poorten V, Triantafyllou A, Thompson LD, Bishop J, Hauben E, Hunt J et al (2016) Salivary acinic cell carcinoma: reappraisal and update. Eur Arch Otorhinolaryngol 273(11):3511–3531
doi: 10.1007/s00405-015-3855-7
Quer M, Guntinas-Lichius O, Marchal F, Vander Poorten V, Chevalier D, León X et al (2016) Classification of parotidectomies: a proposal of the European Salivary Gland Society. Eur Arch Otorhinolaryngol 273(10):3307–3312
doi: 10.1007/s00405-016-3916-6
Scherl C, Kato MG, Erkul E et al (2018) Outcomes and prognostic factors for parotid acinic cell Carcinoma: A National Cancer Database study of 2362 cases. Oral Oncol 82:53–60
doi: 10.1016/j.oraloncology.2018.05.002
Park YM, Yoon SO, Kim JH et al (2021) Comprehensive analysis of clinicopathologic factors predictive of an unfavorable prognosis in patients with acinic cell carcinoma of the parotid gland. Clin Exp Otorhinolaryngol 14(1):108–115
doi: 10.21053/ceo.2019.01550
van Weert S, Valstar M, Lissenberg-Witte B et al (2022) Prognostic factors in acinic cell carcinoma of the head and neck: the Amsterdam experience. Oral Oncol 125:105698
doi: 10.1016/j.oraloncology.2021.105698
Grasl S, Janik S, Grasl MC et al (2019) Nodal metastases in acinic cell carcinoma of the parotid gland. J Clin Med 8(9):1315
doi: 10.3390/jcm8091315
Moon P, Tusty M, Divi V et al (2021) Significance of nodal metastasis in parotid gland acinar cell carcinoma. Laryngoscope 131(4):E1125–E1129
doi: 10.1002/lary.28966
Sideris A, Rao A, Maher N et al (2021) Acinic cell carcinoma of the salivary gland in the adult and paediatric population: a survival analysis. ANZ J Surg 91(6):1233–1239
doi: 10.1111/ans.16421
Gomez DR, Katabi N, Zhung J, Wolden SL, Zelefsky MJ, Kraus DH, Shah JP, Wong RJ, Ghossein RA, Lee NY (2009) Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland. Cancer 115(10):2128–2137
doi: 10.1002/cncr.24259
Andreoli MT, Andreoli SM, Shrime MG et al (2012) Radiotherapy in parotid acinic cell carcinoma: does it have an impact on survival? Arch Otolaryngol Head Neck Surg 138(5):463–466
doi: 10.1001/archoto.2012.226
Zenga J, Parikh AS, Emerick KS et al (2018) Close margins and adjuvant radiotherapy in acinic cell carcinoma of the parotid gland. JAMA Otolaryngol Head Neck Surg 144(11):1011–1016
doi: 10.1001/jamaoto.2018.0788
Kovarik JP, Voborna I, Barclay S, et al (2021) Osteoradionecrosis after treatment of head and neck cancer: a comprehensive analysis of risk factors with a particular focus on role of dental extractions. Br J Oral Maxillofac Surg. S0266-4356(21)00120-0
Dracham CB, Shankar A, Madan R (2018) Radiation induced secondary malignancies: a review article. Radiat Oncol J 36(2):85–94
doi: 10.3857/roj.2018.00290
Schoenfeld JD, Sher DJ, Norris CM Jr et al (2012) Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys 82(1):308–314
doi: 10.1016/j.ijrobp.2010.09.042
Liu Y, Su M, Yang Y et al (2017) Prognostic factors associated with decreased survival in patients with acinic cell carcinoma of the parotid gland. J Oral Maxillofac Surg 75(2):416–422
doi: 10.1016/j.joms.2016.06.185
Kirschnick LB, Silveira FM, Schuch LF et al (2021) Clinicopathological analysis of oral and maxillofacial acinic cell carcinoma: a systematic review. J Oral Pathol Med 50(8):741–749
doi: 10.1111/jop.13159

Auteurs

Pietro De Luca (P)

Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy. dr.dlp@hotmail.it.
Department Otolaryngology Head and Neck Surgery, San Giovanni-Addolorata Hospital, Rome, Italy. dr.dlp@hotmail.it.

Luca de Campora (L)

Department Otolaryngology Head and Neck Surgery, San Giovanni-Addolorata Hospital, Rome, Italy.

Domenico Tassone (D)

Department Otolaryngology Head and Neck Surgery, San Giovanni-Addolorata Hospital, Rome, Italy.

Francesca Atturo (F)

Department Otolaryngology Head and Neck Surgery, San Giovanni-Addolorata Hospital, Rome, Italy.

Roberta Colangeli (R)

Department Otolaryngology Head and Neck Surgery, San Giovanni-Addolorata Hospital, Rome, Italy.

Gerardo Petruzzi (G)

Department Otolaryngology Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy.

Matteo Fermi (M)

Department of Otorhinolaryngology-Head and Neck Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Department of Specialist, Diagnostic and Experimental Medicine, Alma Mater Studiorum University, Bologna, Italy.

Giulia Molinari (G)

Department of Otorhinolaryngology-Head and Neck Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Andi Abeshi (A)

Department of Otorhinolaryngology-Head and Neck Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Giulia Cintoli (G)

Department of Otolaryngology-Head and Neck Surgery, University of Foggia, Foggia, Italy.

Alfredo Lo Manto (A)

Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital of Modena, Modena, Italy.

Giulia Togo (G)

Maxillofacial Surgery Unit, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II, Naples, Italy.

Filippo Ricciardiello (F)

Otolaryngology Department, AORN Cardarelli, Naples, Italy.

Paolo Condorelli (P)

Otolaryngology Department, AORN Garibaldi, Catania, Italy.

Ferdinando Raso (F)

Otolaryngology Department, AORN Garibaldi, Catania, Italy.

Arianna Di Stadio (A)

Otolaryngology Department, University of Catania, Catania, Italy.

Giovanni Salzano (G)

Otolaryngology and Maxillo-Facial Surgery Unit, Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy.

Erik Esposito (E)

Otolaryngology Department, ASL Napoli 3 Sud, Torre del Greco, Naples, Italy.

Aurelio D'Ecclesia (A)

IRCCS "Casa Sollievo Della Sofferenza" San Giovanni Rotondo, Foggia, Italy.

Marco Radici (M)

Unit of Otolaryngology, S. Giovanni Calibita-Fatebenefratelli General Hospital, Rome, Italy.

Maurizio Iemma (M)

Otolaryngology Department, San Giovanni di Dio e Ruggi D'Aragona University Hospital, Salerno, Italy.

Maurizio Giovanni Vigili (MG)

Department of General Surgery-Head and Neck Consultant, Istituto Dermopatico Dell'Immacolata IDI-IRCCS, Rome, Italy.

Francesco Antonio Salzano (FA)

Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.

Luciano Magaldi (L)

Department of Otolaryngology-Head and Neck Surgery, University of Foggia, Foggia, Italy.

Michele Cassano (M)

Department of Otolaryngology-Head and Neck Surgery, University of Foggia, Foggia, Italy.

Iacopo Dallan (I)

Department of Otorhinolaryngology, Azienda Ospedaliera Universitaria, Pisa, Italy.

Raul Pellini (R)

Department Otolaryngology Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy.

Livio Presutti (L)

Department of Otorhinolaryngology-Head and Neck Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Franco Ionna (F)

Otolaryngology and Maxillo-Facial Surgery Unit, Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy.

Enrico de Campora (E)

Associazione Ospedaliera Italia Centromeridionale Otorinolaringoiatrica (AOICO), Rome, Italy.

Angelo Camaioni (A)

Department Otolaryngology Head and Neck Surgery, San Giovanni-Addolorata Hospital, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH